Tris Pharma Inc. can’t be sued by the state of Texas for manipulating test results on medication to treat minors for attention-deficit/hyperactivity disorder, a state appeals court ruled Tuesday.
Tris, a New Jersey based company, doesn’t manufacture or market its drug Quillivant in Texas, and as a result it lacks a meaningful connection to the state, the Court of Appeals, Fifteenth District, decided.
Reversing a district court that ruled to keep Tris in the lawsuit, the appeals court noted that the company’s founder, Ketan Mehta, reached out to only three Texas physicians to promote the drug between 2013 and 2018. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.